Short-term Effect of Intravitreal Dexamethasone Implant in Refractory Diabetic Macular Edema - Trial NCT05736081
Access comprehensive clinical trial information for NCT05736081 through Pure Global AI's free database. This Phase 2/3 trial is sponsored by Asociación para Evitar la Ceguera en México and is currently Completed. The study focuses on Diabetic Macular Edema. Target enrollment is 15 participants.
This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.
Study Focus
Sponsor & Location
Asociación para Evitar la Ceguera en México
Timeline & Enrollment
Phase 2/3
Feb 15, 2018
Jun 30, 2019
Primary Outcome
Change in central retinal thickness
Summary
The goal of this clinical trial es to learn about the short term effects of intravitreal
 dexamethasone implant (IDI) in patients with refractory diabetic macular edema. The main
 question it aims to answer is:
 
 How fast does the diminishing in central retinal thickness has statistical significance after
 IDI in patients with refractory diabetic macular edema? Patients will be evaluated by OCT
 before and after the implant.
ICD-10 Classifications
Data Source
ClinicalTrials.gov
NCT05736081
Non-Device Trial